Plot No.367, Abhey Pur, Industrial Area Phase-1, Panchkula, Haryana 134109
Don't miss out on this limited-time offer to join our successful PCD Pharma network. Fill in your details below and our team will get in touch with you to discuss the best franchise opportunities tailored to your needs.
Ceftriaxone (250mg) + Tazobactum (31.25mg)
Therapeutic Category
Antibacterials, Antibiotic, Dermatology, Gastroenterology, General and OTC medicines, Pulmonary, Respiratory, Urology, Pediatrics
Dosage Form
Injection
Packaging Type
Vial + Water
Packaging
281.25mg
Price
₹92/-
High-resolution images and Product visuals
Product overview and usage information
Detailed information and research documents
Fritcet TZ 281.25 Injection combines the potent antibiotic ceftriaxone with tazobactam, designed to enhance its efficacy against a broad spectrum of bacterial infections. Ceftriaxone is a third-generation cephalosporin that targets gram-positive and gram-negative bacteria, making it effective for various infections, including respiratory, urinary tract, and skin infections. Tazobactam, a beta-lactamase inhibitor, safeguards ceftriaxone from degradation by certain bacteria, thereby improving its effectiveness in treating resistant strains.
This injectable formulation is particularly valuable in hospital settings, where it is used to manage serious infections, including those associated with sepsis and surgical procedures. Administered intravenously or intramuscularly, Fritcet TZ 281.25 ensures rapid delivery of the active ingredients, promoting quick therapeutic action.
Potential side effects may include allergic reactions, gastrointestinal disturbances, and changes in liver enzyme levels. Monitoring is recommended during therapy.
Fritcet TZ 281.25 Injection is indicated for the treatment of moderate to severe bacterial infections, including pneumonia, skin infections, and intra-abdominal infections.
Consult a healthcare professional before use, especially in patients with a history of allergies to beta-lactam antibiotics. In summary, Fritcet TZ 281.25 Injection stands out as a reliable option for clinicians seeking to combat challenging bacterial infections. Its dual-action formula addresses the increasing concern of antibiotic resistance, providing a robust treatment choice in acute care settings. Always follow healthcare guidance regarding dosing and administration to ensure optimal outcomes and minimize risks associated with therapy.
Store at room temperature, away from light and moisture. Do not freeze.
Composition : Ceftriaxone (1000mg) + Sulbactam (500mg)
Composition : Ceftriaxone (125mg) Injection
Composition : Ceftriaxone (250mg)
Composition : Ceftriaxone (250mg) + Sulbactam (125mg)
Composition : Ceftriaxone (500mg)
Composition : Ceftriaxone (500mg) + Sulbactam (250mg)
Composition : Cefuroxime (1500mg)
Composition : Cefuroxime (1.5gm)
Composition : Cefuroxime (1500mg) + Sulbactam (750mg)
Composition : Clarithromycin (500mg) Injection
This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.
Ceftriaxone 250mg + Tazobactam 31.25mg Injection has strong demand in the hospital, anti-infective, and critical care segment, making it a valuable product for medical distributors, wholesalers, and pharma franchise partners focusing on advanced injectable antibiotics and institutional healthcare portfolios.
Medical distributors and agencies can benefit from consistent demand for bacterial infection management under medical supervision. Ceftriaxone 250mg is a third-generation cephalosporin antibiotic with broad-spectrum antibacterial activity Tazobactam 31.25mg is a beta-lactamase inhibitor that helps enhance the effectiveness of ceftriaxone against resistant bacterial strains Commonly prescribed for respiratory tract infections, urinary tract infections, skin and soft tissue infections, intra-abdominal infections, and other susceptible bacterial infections Widely used in hospitals, clinics, and healthcare institutions for effective infection management Injectable formulation ensures rapid therapeutic action and reliable clinical outcomes This strengthens a comprehensive anti-infective and hospital-care portfolio.
Yes, Cafoli LifeCare Pvt Ltd offers PCD pharma franchise opportunities for Ceftriaxone 250mg + Tazobactam 31.25mg Injection with promotional support, monopoly rights, attractive packaging, and competitive pricing for distributors and wholesaler
Wholesalers and medical agencies benefit from strong hospital demand, institutional procurement opportunities, repeat orders, reliable supply chain support, high market acceptance, and attractive margins in the injectable antibiotic segment.
Interested distributors, stockists, and wholesalers can contact Cafoli LifeCare Pvt Ltd to explore PCD pharma franchise opportunities, discuss pricing and business terms, obtain monopoly territory rights, and benefit from comprehensive marketing support, quality pharmaceutical products, and a dependable supply chain to grow their business successfully.